medigraphic.com
Academia Mexicana de Neurología, A.C.

2006, Number 6

<< Back Next >>

Rev Mex Neuroci 2006; 7 (6)

Notes on inmunopathological mechanisms in Guillain-Barré’s syndrome

Cardoso-Suárez T, Robinson-Agramonte MÁ

Language: Spanish
References: 30
Page: 599-603
PDF size: 137.04 Kb.


ABSTRACT

Demyelinating diseases are characterized for being acquired inflammatory processes, that selectively affect myelin of central and peripheral nervous weave. Its occurrence in humans includes a variety of acute and subacute inflammatory processes, between which are: optical neuromyelitis, acute disseminated encephalomyelitis and acute inflammatory polyrradiculoneuropathy or Guillain-Barré’s syndrome (GBS). Molecular mimicry between environmental agents as C. jejuni and molecules of peripheral nerves seems to be an important element in the production of this disease of autoinmune profile. There are left questions as why in the GBS the axonal and myelin damage is restricted to the NPS and others like lymphocytes T paper in the pathogenesis of GBS.


REFERENCES

  1. Lucchinetti C. The spectrum of idiopathic inflammatory demyelinating disease. Am Academy of Neurology. Syllabi on CD ROM. 2000. Ref Type: Electronic Citation.

  2. Onuki M, Ayers MM, Bernard CC, Orian JM. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice. Microsc Res Tech 2001; 52: 731-9.

  3. Ho TW, et al. Human autoimmune neuropathies. Annu Rev Neurosci 1998; 21: 187-226.

  4. Stojkovic T, Dubucquoi S. The use of intravenous immunoglobulins in neurology. Rev Neurol (Paris) 2005; 161: 781-94.

  5. Van Doorn PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2005; 10: 113-27.

  6. Green DM. Advances in the management of Guillain-Barre syndrome. Curr Neurol Neurosci Rep 2002; 2: 541-8.

  7. Zhang G, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127: 1085-100.

  8. Hadden RD, Cornblath DR, Hughes RA. Electrophysiological classification of Guillain-Barré syndrome: a reappraisal. Ann Neurol 1998; 44: 780-8.

  9. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005; 366: 1653-66.

  10. Guillain-Barre syndrome: an Italian multicentre case-control study. Guillain-Barre Syndrome Study Group. Neurol Sci 2000; 21: 229-34.

  11. McCarthy N, Giesecke J. Incidence of Guillain-Barre syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153: 610-14.

  12. Haber P, et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004; 292: 2478-81.

  13. Ogawara K, et al. Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. J Neurol Sci 2003; 210: 41-5.

  14. Kuwabara S, et al. Differences in membrane properties of axonal and demyelinating Guillain-Barre syndromes. Ann Neurol 2002; 52: 180-7.

  15. Goodfellow JA, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005; 25: 1620-8.

  16. Kuwabara S, et al. Does Campylobacter jejuni infection elicit «demyelinating» Guillain-Barre syndrome? Neurology 2004; 63: 529-33.

  17. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-625.

  18. Kwa MS, et al. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 2003; 126: 361-75.

  19. Hafer-Macko, CE, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39: 625-35.

  20. Yuki N, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 2004; 101: 11404-9.

  21. Gabriel CM, Hughes RAC, Moore SE, Walsh FS. Induction of experimental neuritis with peripheral myelin protein 22. Brain 1998; 121: 1895-902.

  22. Putzu GA, et al. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci 2000; 174: 16-21.

  23. Creange A, et al. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome. Neurology 1999; 53: 1683-91.

  24. Sharshar T, et al. MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barre syndrome. Neurology 2002; 59: 1649-51.

  25. Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25: 61-6.

  26. Gong Y, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002; 125: 2491-506.

  27. Godschalk PC, et al. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. J Clin Invest 2004; 114: 1659-65.

  28. Yuki N, Odaka M, Ganglioside mimicry as a cause of Guillain-Barre syndrome. Curr Opin Neurol 2005; 18: 557-61.

  29. Cavanna B, et al. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. J Neuroimmunol 2001; 114: 226-31.

  30. Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 2003; 126: 2034-42.




2020     |     www.medigraphic.com